Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Madison Small Cap Fund Faraz Farzam, Aaron Garcia | “Alphatec ($ATEC) is a medical technology company specializing in spine surgery solutions, recognized for pioneering the prone transpsoas (PTP) technique. This minimally invasive surgical approach accesses the patient's spine from the lateral side while keeping them in a prone position, significantly reducing operative complication rates and accelerating post-surgery rehabilitation relative to legacy lateral approaches. The manager holds a high-conviction bullish thesis, capitalizing on temporary revenue growth deceleration across late 2025 and early 2026 to initiate a core position. From a financial and competitive mechanics standpoint, Alphatec is systematically taking market share from legacy medical technology conglomerates like Medtronic, Johnson & Johnson, and Globus Medical. The business exhibits high operating leverage, where expanding procedure volume and surgeon adoption across its specialized procedural suites should unlock dramatic operating margin expansion as revenue scales over its fixed corporate and distribution infrastructure. The management team demonstrates an owner-operator mentality with strong alignment to shareholder capital efficiency. Key catalysts to monitor include ongoing market share gains, expanding adoption of the PTP platform, and inflection into consistent operating profitability and free cash flow generation. Primary risks center on potential regulatory friction, pricing pressure from hospital purchasing organizations, and competitive counter-responses from larger diversified orthopedic equipment peers.” | BULL | Q3 2026 Oct 12, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.